Precision BioSciences Anticipates Beginning Patient Dosing for Duchenne Muscular Dystrophy in The Early Second Quarter of 2026
For the DMD program PBGENE-DMD, Precision BioSciences anticipates starting patient dosing in late first or early second quarter of 2026, following expected IND approval....
Entrada Therapeutics Announced It will Report Data from its Exon Skipping Studies in 2026
According to Entrada Therapeutics' announcement, "2026 will be a data-rich year for Duchenne muscular dystrophy; data from the first cohort of ELEVATE-44-201 is expected...
Nxera Pharma Licenses Japan and Select Asia-Pacific Rights to Vamorolone for Duchenne Muscular Dystrophy from Santhera Pharmaceuticals
Nxera Pharma (“Nxera” or “the Company; TSE 4565) announces that it has entered an exclusive licensing agreement for the development, manufacturing and commercialization of...
Italfarmaco and JCR Pharmaceuticals Announce Commercialisation Agreement for Duvyzat (Givinostat) in Japan and Strategic Collaboration in Rare Disease
Italfarmaco and JCR Pharmaceuticals announced an exclusive licensing agreement for the development and commercialisation of Duvyzat (Givinostat) in Japan.Under the terms of the agreement,...
Secretary Kennedy Expands Newborn Screening to Include Duchenne Muscular Dystrophy in USA
Duchenne muscular dystrophy (Duchenne) has been officially added to the Recommended Uniform Screening Panel (RUSP) by the U.S. Department of Health and Human Services...